# BioMedNewsBreaks — Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Receives Australian Approval to Begin EMBRACE Phase 3 Study of CYB003

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company focused on next-generation treatment options, announced approval in Australia to conduct the EMBRACE study, the second pivotal trial in PARADIGM, its Phase 3 multinational program evaluating CYB003, a proprietary deuterated psilocin analog. Approval was granted through the Clinical Trial Notification scheme, with clearance from multiple Ethics Committees of the Australian Therapeutics Goods Administration and Research Governance Offices, allowing initiation of the study.

 To view the full press release, visit https://ibn.fm/lHz40

 About Cybin

 Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.

 With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.

 Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

 NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireAustin, Texaswww.BioMedWire.com512.354.7000 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/biomednewsbreaks-cybin-inc-nyse-american-cybn-cboe-ca-cybn-receives-australian-approval-to-begin-embrace-phase-3-study-of-cyb003/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/cybin-gains-australian-approval-for-phase-3-psychedelic-depression-treatment-trial/6d9a080d462adda0027acda3901cb68c) 

 



[Reddit Post](https://www.reddit.com/r/PsychedelicsNews/comments/1n0ogux/cybin_gains_australian_approval_for_phase_3/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/258/26/rice23lc.webp)